Yong He

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han et al. · Annals of Oncology · 2020 · 276 citations · Full text

Medicine, Oncology, Pharmacology +15

Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China

Xue Zhang, Fang Wang, Ye Shen et al. · JAMA Network Open · 2021 · 255 citations · Full text

Veterinary Medicine, Infectious Diseases, Disease Surveillance +12

Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> through Inhibition of IL-6 Signaling and EMT Reversal

Li Li, Rui Han, Hualiang Xiao et al. · Clinical Cancer Research · 2014 · 234 citations

Medicine, Oncology, Pharmacology +16